AMNOG, the 2011 law that governs new-drug pricing, makes Germany unique: you launch at a price you choose, and the system then decides, on a fixed clock, what your evidence was worth. The pathway below covers who decides, what they weigh, and when you can still influence the outcome.
The odds, from 521 novel EMA authorisations 2011–2020
Reimbursement follows authorisation by default in Germany; the rating decides the price, not access. This is the hardest rating gate of the five. Posterior means with 90% credible intervals from our Bayesian pathway model; segment-level odds by technology, disease area and first-in-class status are in the subscription.
The pathway, step by step
Regulatory approval: EMA (or BfArM/PEI)
Most new active substances come through the EMA centralised procedure; BfArM (or PEI for biologics and vaccines) handles national routes. Approval is the entry ticket; Germany has no separate reimbursement gate. From 2025, oncology and ATMP assets also receive an EU Joint Clinical Assessment, whose evidence package feeds the national process.
Engage: parallel EMA/HTA scientific advice: endpoint choices made in phase III decide the German outcomeComparator advice: the G-BA consultation
The single highest-leverage meeting in the pathway. The G-BA advises on the zweckmäßige Vergleichstherapie (ZVT), the comparator your evidence will be judged against, plus relevant subpopulations and endpoints. A trial designed against the wrong comparator is the most common reason good drugs get "no added benefit".
Engage: G-BA Beratungsgespräch (formal advice meeting, fee-based)Free pricing begins; the dossier is due immediately
You set your own launch price and are reimbursed at it. The full benefit dossier (Modules 1-5) must be submitted at launch. There is no grace period, and an incomplete dossier is treated as evidence of no added benefit.
Free-pricing window: 6 months of cash-flow, not 12. Plan for month-7 retroactivityIQWiG assessment published
IQWiG, the independent institute, reviews the dossier and publishes its assessment of added benefit by subpopulation, with an evidence-certainty grade (Beleg / Hinweis / Anhaltspunkt). It is advisory, but the G-BA follows its direction in most cases. Written and oral hearings follow, and they do change outcomes at the margins.
Engage: written statement + oral hearing: the last formal influence pointG-BA resolution: the rating that sets your price corridor
The G-BA resolves added benefit on a five-step ladder per subpopulation: major → considerable → minor → non-quantifiable → not proven. Orphan drugs enter with added benefit deemed proven at approval, but they lose that privilege above €30m annual sales, when a full assessment against the ZVT follows.
Our data: 55% of resolutions end "not proven" · only 18 of 1,039 ever rated majorPrice negotiation with the GKV-Spitzenverband
The rating now becomes money. Statutory guardrails bind the negotiation: no added benefit means the reimbursed price cannot exceed the comparator's cost; minor or non-quantifiable ratings against generic comparators are capped near comparator level. The agreed price applies retroactively from month 7. Since the 2024 Medical Research Act, companies with a German research footprint may opt for a confidential reimbursement price, at the cost of an additional 9% discount.
Combinations: 20% statutory discount applies to each on-patent partnerArbitration: the Schiedsstelle
If negotiation fails, the arbitration board sets the price, typically anchored to European reference prices and the rating. Companies unhappy with the outcome can withdraw from the market (opt-out), a step several have taken rather than accept the arbitrated price.
Reference pricing, prescribing controls and re-assessment
No-added-benefit products with off-patent comparators can be pulled into a Festbetrag (reference price) cluster. Regional prescribing economics (Wirtschaftlichkeitsprüfung) shape uptake. New indications, new evidence, or the €30m orphan threshold trigger fresh assessments. German market access is a process, not an event.
What the record actually shows
Who decides what, and when to engage
| Institution | What it decides | Evidence it weighs | When to engage |
|---|---|---|---|
| EMA / BfArM / PEI Regulators | Approval and label: the boundary of everything downstream | Efficacy, safety, quality | Scientific advice in phase II/III; parallel EMA, HTA advice where possible |
| G-BA Joint Federal Committee | The ZVT, the subpopulations, and the added-benefit rating | RCTs vs the ZVT; patient-relevant endpoints (mortality, morbidity, quality of life, safety); surrogates are discounted | Beratungsgespräch before phase III; hearings at months 3-6 |
| IQWiG Assessment institute | The technical assessment the G-BA leans on | Methods rigour: ITT, subgroups, effect sizes vs certainty grades | Indirectly, through dossier quality and the hearing |
| GKV-Spitzenverband Umbrella of sickness funds | The reimbursed price (Erstattungsbetrag) | The rating, comparator prices, European prices, volumes | Months 7-12; scenario-model the guardrails before launch pricing |
| Schiedsstelle Arbitration board | The price when negotiation fails | European reference prices, the rating | Avoid it; arbitration outcomes are rarely better than negotiation |
| Sickness funds & regional bodies | Prescribing economics, selective contracts | Budget impact in practice | Post-launch; relevant for uptake, not access |
The evidence Germany actually asks for
The dossier is not a regulatory file with a price attached. It is a different argument, judged by different rules:
Head-to-head against the ZVT. Placebo-controlled or single-arm evidence where an active comparator exists is the classic route to "not proven", regardless of how good the drug is. If your pivotal trial can't be renegotiated, indirect comparisons need to be methodologically watertight and pre-agreed where possible.
Patient-relevant endpoints. The German system discounts surrogates that regulators accept. Mortality, morbidity, quality of life (with validated instruments), and safety carry the assessment; PFS alone rarely does.
Subpopulations, sized. The G-BA rates by subgroup, and the price negotiation weights ratings by subgroup size, which makes German epidemiology (registry-grade, not modelled) part of the pricing argument, not background colour.
The economic case comes later. Unlike NICE, there is no cost-effectiveness threshold; the economics live in the price negotiation, where comparator cost, European reference prices and budget impact set the corridor your rating earns.
Where companies get hurt
Planning a German launch?
We build the evidence and pricing case AMNOG actually rewards: ZVT strategy, dossier-ready analyses, guardrail-aware price corridors, grounded in the same data you can check on this site. Fixed fees, senior-built.
Talk to us about Germany